Market Overview:
The global Retinitis Pigmentosa (Retinitis) market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth factors include the increasing incidence of Retinitis Pigmentosa, rising awareness about Retinitis Pigmentosa, and technological advancements in the field of gene therapy and surgical treatment. However, high costs associated with gene therapy and surgical treatment are likely to restrain the growth of this market during the forecast period. The global Retinitis Pigmentosa (Retinitis) market can be segmented on the basis of type into general treatment, traditional Chinese medicine, gene therapy, surgical treatment, and other treatments. The general treatment segment is expected to dominate this market during the forecast period owing to its large customer base and widespread use across all regions. However, gene therapy is expected to grow at a higher CAGR than any other type during the forecast period as it offers better results with fewer side effects as compared to other treatments available in this market.
 Industry Outlook.svg)
Product Definition:
A progressive eye disease that causes the retina to deteriorate, leading to vision loss. Retinitis pigmentosa (retinitis) is a condition in which the retina at the back of your eye gradually breaks down, leading to vision loss. It usually starts with difficulty seeing in low light and progresses over time to complete blindness.
General Treatment:
Retinitis pigmentosa (RP) is a rare genetic disorder that affects the retina, leading to progressive vision loss. The disease has an incidence of 1 in 40,000 people and generally occurs in men between the age group of 20-60 years and women between the age group of 15-40 years.
The major symptoms associated with RP are night blindness, visual acuity decline,.
Traditional Chinese Medicine:
Traditional Chinese Medicine (TCM) is the traditional medical system of China. It has been used to treat patients suffering from retinitis pigmentosa (RP) for over 2000 years. TCM holds a wealth of information on the treatment and management of RP along with other ophthalmic conditions. The use of herbs, acupuncture, massage and moxa in combination with each other and drugs have been used to effectively treat RP over the past two thousand years.
Application Insights:
Based on application, the market is segmented into hospitals, eye clinics, and others. The hospital segment dominated the market in 2017 owing to a large patient base that requires treatment for Retinitis Pigmentosa (Retinitis). In addition, this condition is considered an emergency as early diagnosis of RP allows appropriate treatment at its early stages. This factor has led to a significant share of the hospital segment in terms of revenue.
The eye clinic segment is expected to grow at a lucrative rate during the forecast period due to increasing awareness about retinal diseases and growing prevalence rates of RP among all age groups globally. For instance, according Retina Canada: ¢â‚¬Å“In 2016-2017 there were more than 1 million people diagnosed with retinitis pigmentosa across all ages groupings worldwide which was around 90% amongst patients above 60 years¢â‚¬ (as cited in Vision 2020 article).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, advanced healthcare infrastructure, rising prevalence of retinal diseases and increasing adoption of new treatment methods are some factors driving regional growth. Moreover, growing awareness about various treatments available for retinitis pigmentosa is expected to further fuel the market over the forecast period.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to untapped opportunities in this region. There has been an increase in research funding for Retinitis Pigmentosa (Retinitis) condition by government organizations such as National Eye Institute (NIH), U.S.
Growth Factors:
- Increasing prevalence of Retinitis Pigmentosa (Retinitis) due to growing aging population.
- Rising awareness about Retinitis Pigmentosa (Retinitis) and its early diagnosis and treatment options among people.
- Technological advancements in the field of ophthalmology that are helping in the diagnosis and treatment of Retinitis Pigmentosa (Retinitis).
- Growing number of research studies on Retinitis Pigmentosa (Retinis) providing new insights into the disease pathogenesis and potential treatments options.
Scope Of The Report
Report Attributes
Report Details
Report Title
Retinitis Pigmentosa (Retinitis) Market Research Report
By Type
General Treatment, Traditional Chinese Medicine, Gene Therapy, The Surgical Treatment, Other,
By Application
Hospitals, Eye Clinics, Other,
By Companies
Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, M's Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics, Sun Pharma Advanced Research Company,
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Retinitis Pigmentosa (Retinitis) Market Report Segments:
The global Retinitis Pigmentosa (Retinitis) market is segmented on the basis of:
Types
General Treatment, Traditional Chinese Medicine, Gene Therapy, The Surgical Treatment, Other,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Eye Clinics, Other,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Amgen
- Amarantus Bioscience Holdings
- Acucela
- Applied Genetic Technologies Corp
- Asklepios BioPharmaceutical
- Astellas Pharma
- Caladrius Biosciences
- Dompe Farmaceutici SpA
- Dormant Projects
- GenSight Biologics SA
- Grupo Ferrer Internacional SA
- ID Pharma
- InFlectis BioScience
- Ionis Pharmaceuticals
- Mimetogen Pharmaceuticals
- M's Science Corp
- Nanovector srl
- Novartis AG
- Novelion Therapeutics
- ProQR Therapeutics
- ReNeuron Group Plc
- SanBio
- Shire (Takeda Pharmaceutical)
- Spark Therapeutics
- Sun Pharma Advanced Research Company
 Market Overview.svg)
Highlights of The Retinitis Pigmentosa (Retinitis) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- General Treatment
- Traditional Chinese Medicine
- Gene Therapy
- The Surgical Treatment
- Other
- By Application:
- Hospitals
- Eye Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Retinitis Pigmentosa (Retinitis) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Retinitis pigmentosa is a disorder of the retina, which is the light-sensitive layer at the back of your eye. The retina can become damaged over time, leading to gradual vision loss. In severe cases, blindness may occur.
Some of the major companies in the retinitis pigmentosa (retinitis) market are Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, M's Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics, Sun Pharma Advanced Research Company.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Retinitis Pigmentosa (Retinitis) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Retinitis Pigmentosa (Retinitis) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Retinitis Pigmentosa (Retinitis) Market - Supply Chain
4.5. Global Retinitis Pigmentosa (Retinitis) Market Forecast
4.5.1. Retinitis Pigmentosa (Retinitis) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Retinitis Pigmentosa (Retinitis) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Retinitis Pigmentosa (Retinitis) Market Absolute $ Opportunity
5. Global Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Type
5.3.1. General Treatment
5.3.2. Traditional Chinese Medicine
5.3.3. Gene Therapy
5.3.4. The Surgical Treatment
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Eye Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Retinitis Pigmentosa (Retinitis) Demand Share Forecast, 2019-2026
9. North America Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Eye Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Type
9.7.1. General Treatment
9.7.2. Traditional Chinese Medicine
9.7.3. Gene Therapy
9.7.4. The Surgical Treatment
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Retinitis Pigmentosa (Retinitis) Demand Share Forecast, 2019-2026
10. Latin America Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Eye Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Type
10.7.1. General Treatment
10.7.2. Traditional Chinese Medicine
10.7.3. Gene Therapy
10.7.4. The Surgical Treatment
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Retinitis Pigmentosa (Retinitis) Demand Share Forecast, 2019-2026
11. Europe Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Eye Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Type
11.7.1. General Treatment
11.7.2. Traditional Chinese Medicine
11.7.3. Gene Therapy
11.7.4. The Surgical Treatment
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Retinitis Pigmentosa (Retinitis) Demand Share, 2019-2026
12. Asia Pacific Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Eye Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Type
12.7.1. General Treatment
12.7.2. Traditional Chinese Medicine
12.7.3. Gene Therapy
12.7.4. The Surgical Treatment
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Retinitis Pigmentosa (Retinitis) Demand Share, 2019-2026
13. Middle East & Africa Retinitis Pigmentosa (Retinitis) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Eye Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Retinitis Pigmentosa (Retinitis) Market Size and Volume Forecast by Type
13.7.1. General Treatment
13.7.2. Traditional Chinese Medicine
13.7.3. Gene Therapy
13.7.4. The Surgical Treatment
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Retinitis Pigmentosa (Retinitis) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Retinitis Pigmentosa (Retinitis) Market: Market Share Analysis
14.2. Retinitis Pigmentosa (Retinitis) Distributors and Customers
14.3. Retinitis Pigmentosa (Retinitis) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Amarantus Bioscience Holdings
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Acucela
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Applied Genetic Technologies Corp
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Asklepios BioPharmaceutical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Astellas Pharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Caladrius Biosciences
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Dompe Farmaceutici SpA
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Dormant Projects
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. GenSight Biologics SA
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Grupo Ferrer Internacional SA
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. ID Pharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. InFlectis BioScience
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Ionis Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Mimetogen Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. M's Science Corp
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Nanovector srl
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Novartis AG
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Novelion Therapeutics
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
